{"id":"bbv154-intranasal-covaxin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion or rhinitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Local nasal irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BBV154 delivers viral antigens via the intranasal route to stimulate mucosal and systemic immunity, complementing the intramuscular Covaxin primary series. This heterologous prime-boost strategy aims to broaden and strengthen neutralizing antibody responses and T-cell immunity against COVID-19, potentially improving protection against emerging variants.","oneSentence":"BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:47.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention as a booster dose in Covaxin-primed individuals"}]},"trialDetails":[{"nctId":"NCT05639998","phase":"PHASE2","title":"BBV152/BBV154 Heterologus Prime-Boost Study","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2021-09-01","conditions":"Corona Virus Infection","enrollment":608},{"nctId":"NCT05567471","phase":"PHASE3","title":"Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2022-02-26","conditions":"COVID-19 Respiratory Infection","enrollment":875},{"nctId":"NCT05522335","phase":"PHASE3","title":"Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Bharat Biotech International Limited","startDate":"2022-04-16","conditions":"COVID-19 Respiratory Infection","enrollment":3160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BBV154(Intranasal) & covaxin","genericName":"BBV154(Intranasal) & covaxin","companyName":"Bharat Biotech International Limited","companyId":"bharat-biotech-international-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming. Used for COVID-19 prevention as a booster dose in Covaxin-primed individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}